FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1529-1538 April 14, 2005 Number 15 Next

Abstract PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Pedersen-Bjergaard, J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Chromosomal translocations leading to chimeric oncoproteins are important in leukemogenesis, but how they form is unclear. We studied acute promyelocytic leukemia (APL) with the t(15;17) translocation that developed after treatment of breast or laryngeal cancer with chemotherapeutic agents that poison topoisomerase II.

Methods We used long-range polymerase chain reaction and sequence analysis to characterize t(15;17) genomic breakpoints in therapy-related APL. To determine whether topoisomerase II was directly involved in mediating breaks of double-stranded DNA at the observed translocation breakpoints, we used a functional in vitro assay to examine topoisomerase II–mediated cleavage in the normal homologues of the PML and RARA breakpoints.

Results Translocation breakpoints in APL that developed after exposure to mitoxantrone, a topoisomerase II poison, were tightly clustered in an 8-bp region within PML intron 6. In functional assays, this "hot spot" and the corresponding RARA breakpoints were common sites of mitoxantrone-induced cleavage by topoisomerase II. Etoposide and doxorubicin also induced cleavage by topoisomerase II at the translocation breakpoints in APL arising after exposure to these agents. Short, homologous sequences in PML and RARA suggested the occurrence of DNA repair by means of the nonhomologous end-joining pathway.

Conclusions Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomerase II poisons.

The transforming function of leukemia-associated fusion proteins has been widely studied, but little is known about the mechanisms that cause the underlying translocations. Insights can be gained from investigations of therapy-related leukemias, all of which have counterparts in primary leukemias. Exposure to drugs that poison topoisomerase II — the anthracyclines daunorubicin, doxorubicin, and epirubicin; the anthracenedione mitoxantrone; and epipodophyllotoxins such as etoposide — predisposes patients to secondary leukemias with balanced chromosomal rearrangements, including MLL translocations involving band 11q23, t(8;21), inv(16), t(15;17), t(9;22), and NUP98 translocations involving band 11p15.^5,6,7 The association of such chromosomal rearrangements with exposure to drugs that affect topoisomerase II suggests a role for topoisomerase II–mediated cleavage of DNA in forming translocations, but how this occurs remains to be established.

Topoisomerase II relaxes supercoiled DNA by cleaving and religating both strands of the double helix through the formation of a transient covalent cleavage intermediate.⁸ Chemotherapeutic drugs termed "topoisomerase II poisons" convert topoisomerase II into a DNA-damaging enzyme. They disrupt the cleavage–religation equilibrium and thereby increase the concentration of topoisomerase II–mediated cleavage complexes.⁸ Although the enzyme does not have a known DNA recognition sequence that it is most likely to target, genomic sequencing studies have suggested possible binding sites for the enzyme at translocation breakpoints in primary and treatment-related leukemias with MLL, AML1-ETO, PML-RARA, and NUP98 rearrangements.^{9,10,11,12,13,14,15}

In early studies, less than 5 percent of APL cases were a consequence of chemotherapy,^16,17 but more recently, the European APL group reported that therapy-related APL accounted for 22 percent of all cases.¹⁷ The rising incidence of therapy-related APL parallels the increased use of topoisomerase II poisons, particularly in the treatment of breast cancer. APL with t(15;17) is one of the most frequent secondary cancers that arise after the treatment of breast cancer^17,18,19,20; mitoxantrone has been implicated in almost half these cases.^17,19,20 In the present study, we examined genomic breakpoint regions in patients with APL after exposure to topoisomerase II poisons, particularly mitoxantrone, and used functional assays to gain further insight into mechanisms underlying the formation of the t(15;17) chromosomal translocation.

Methods

Patients and Samples

Genomic breakpoint locations in PML and RARA genes were studied in six patients with therapy-related APL, which arose after mitoxantrone treatment for breast carcinoma (in five) or multiple sclerosis (in one). To determine whether breakpoint clustering in PML intron 6 detected in mitoxantrone-related APL was statistically significant, a comparison was made with breakpoint locations in 7 patients with secondary APL arising after other types of exposure, mostly radiotherapy, and in 35 patients with primary APL. Chromosomal breakpoint mechanisms were subsequently investigated with the use of functional topoisomerase II cleavage assays in four of the patients with mitoxantrone-related cases (Patients 1 through 4) and an additional patient (Patient 5) with secondary APL that developed after exposure to doxorubicin and etoposide (Table 1). All patients gave written informed consent, in accordance with the Declaration of Helsinki.

View this table: [in this window] [in a new window]   Table 1. Characteristics of Five Patients with APL Arising after Exposure to Topoisomerase II Poisons.

 
Characterization of Genomic Breakpoints

Three breakpoint regions have been identified within the PML locus in APL: intron 3 (bcr3), exon 6 (bcr2), and intron 6 (bcr1); virtually all breakpoints in RARA occur in intron 2.²¹ The breakpoint pattern in PML was determined by nested reverse-transcriptase polymerase chain reaction (RT-PCR)²²; appropriate primers were used to amplify the sequences of genomic breakpoint junctions by long-range or "bubble" PCR, and the PCR products were sequenced.²¹ Breakpoint junction sequences obtained in this way were confirmed by a patient-specific breakpoint PCR with the use of a fresh aliquot of genomic DNA as template.

In Vitro Topoisomerase II Cleavage Assays

We examined DNA fragments of the normal homologues of PML (GenBank accession numbers S51489 [GenBank] and S57791 [GenBank] ) and RARA (GenBank accession numbers AF088889 [GenBank] and AJ297538 [GenBank] ) that encompassed the relevant translocation breakpoints using an in vitro topoisomerase II cleavage assay.²³ Substrate DNA was incubated with human topoisomerase II in the presence of ATP and exposed to drugs that target topoisomerase II. Final concentrations of etoposide, etoposide catechol, etoposide quinone, and mitoxantrone were 20 µM²⁴; we selected a final concentration of doxorubicin of 25 nM on the basis of a titration using concentrations between 1 nM and 200 nM (data not shown). Cleavage complexes were irreversibly trapped on the addition of sodium dodecyl sulfate, and cleavage products were resolved in a gel containing 8 percent polyacrylamide and 7.0 M urea alongside a DNA-sequencing ladder. This procedure allowed us to map cleavage sites precisely at the sequence level and to analyze the positions of the cleavage sites with respect to translocation breakpoint sites. Cleavage products were visualized by means of autoradiography and quantified with the use of a Phosphorimager and IMAGEQUANT software (Molecular Dynamics).

Statistical Analysis

The significance of the putative mitoxantrone cluster in cases of therapy-related APL or primary plus therapy-related APL was assessed with the use of scan statistics,²⁵ which have been used widely for the assessment of spatial and temporal clustering of events.²⁶ Generally, they are based on the maximal number of events occurring in a prescribed region or interval. This statistic is then referenced against a uniform (null) distribution (over the entire region or period) reflecting the absence of clustering. In the case of translocation breakpoint clustering, the event is the occurrence of a breakpoint, the interval is the number of base pairs spanning the putative cluster, and the reference interval is the relevant intron length.²⁵ Because the distribution of the scan statistic is exceedingly complex, a number of approximations have been developed. Here, we used the accurate, end-point–corrected, large-deviation approximation to the one-dimensional scan statistic.²⁷

Results

Identification of a Translocation Breakpoint Hot Spot in Mitoxantrone-Related APL

Genomic breakpoint junction sequences on the derivative (der) chromosomes 15 and 17 were characterized in APL that arose after mitoxantrone-based treatment for breast cancer in five patients and mitoxantrone treatment for multiple sclerosis in one patient. Remarkably, the der(15) and der(17) PML breakpoints in four of these patients (Patients 1, 2, 3, and 4) (Table 1) were tightly clustered in an 8-bp region (positions 1482 to 1489; GenBank accession number S57791 [GenBank] ) in PML intron 6 (Figure 1 and Figure 2), a result consistent with the presence of a hot spot of DNA damage. Scan statistics indicated that the clustered breakpoints within an intron longer than 1 kb were unlikely to have arisen by chance (P<0.001 for the comparison with 7 cases of APL related to other therapy, P<0.05 for the comparison with the 7 other therapy-related cases plus 35 cases of primary APL, and P<0.05 for the comparison with the 35 cases of primary APL alone).

View larger version (7K): [in this window] [in a new window]   Figure 1. Identification of a Breakpoint Hot Spot in PML Intron 6 in Mitoxantrone-Related APL. Panel A shows the PML intron 6 sequence encompassing mitoxantrone-associated translocation breakpoints, which cluster at positions 1482 to 1489 (shown in black). Panel B shows the distribution of the PML intron 6 genomic translocation breakpoints among the patients with primary and secondary APL, including the translocation breakpoint hot spot in those with mitoxantrone-related APL.

 

View larger version (35K): [in this window] [in a new window]   Figure 2. Genomic Breakpoint Junction Sequences in APL Arising after Exposure to Mitoxantrone. The der(15) and der(17) genomic breakpoint junctions are shown for four patients with mitoxantrone-related APL (Panels A, B, C, and D). The PML and RARA sequences are red and blue, respectively. Vertical lines indicate sequences in derivative chromosomes derived from PML or RARA. Underlines indicate homologies consistent with the occurrence of nonhomologous end-joining. Homologies in green prevented precise localization of breakpoint positions.

 
In contrast to the clustering of the PML breakpoints in cases of mitoxantrone-related APL, the RARA breakpoints were dispersed (Table 1 and Figure 2). Study of the der(15) and der(17) sequences in the four patients with mitoxantrone-related cases associated with the hot spot indicated that the breakpoint junctions were formed without the gain or loss of any bases relative to the native PML and RARA sequences (Figure 2). The short sequence homologies between PML and RARA (underlined in Figure 2) are characteristic of DNA repair by the nonhomologous end-joining pathway (NHEJ),²⁸ which requires minimal overlapping sequences between nonhomologous chromosomes to repair breaks in double-stranded DNA.

Site of Functional Topoisomerase II–Mediated Cleavage at the PML Intron 6 Translocation Breakpoint Hot Spot

We evaluated topoisomerase II–mediated cleavage of the normal homologue of the PML translocation breakpoint hot spot in vitro using a 268-bp double-stranded DNA substrate encompassing the 8-bp hot spot in the presence of mitoxantrone, etoposide or its catechol, or quinone metabolites and in the absence of these agents.²⁴ Few cleavage sites were observed in the absence of drug (Figure 3A). Bands of various sizes and intensities showed where cleavage sites were enhanced by the different agents (Figure 3A).

View larger version (54K): [in this window] [in a new window]   Figure 3. Functional Topoisomerase II Cleavage Sites at Mitoxantrone-Associated Translocation Breakpoints. Chromosomal breakpoint regions were examined by means of a functional in vitro assay, which identifies topoisomerase II–dependent cleavage of DNA induced by various chemotherapeutic agents and their metabolites. Cleavage products were fractionated according to size and compared with a DNA-sequencing ladder to allow precise mapping of sites of DNA cleavage. Panel A shows topoisomerase II–mediated cleavage of DNA substrate spanning positions 1284 to 1551 of PML intron 6 (GenBank accession number S57791 [GenBank] ) encompassing the 8-bp translocation breakpoint hot spot (positions 1482 to 1489). The cleavage products in 25 ng (30,000 cpm) of DNA labeled only at the 5' end were examined after 10 minutes' incubation at 37°C with 147 nM human topoisomerase II, 1 mM ATP, and the following drugs at final concentrations of 20 µM: etoposide (VP16), etoposide catechol (VP16-OH), etoposide quinone (VP16-Q), and mitoxantrone (Mit). Cleavage complexes were irreversibly trapped on the addition of sodium dodecyl sulfate (SDS), and purified cleavage products were resolved in a gel containing 8 percent polyacrylamide and 7.0 M urea, alongside DNA sequencing reactions primed at the same 5' end. Although very few cleavage sites were visible in the absence of drug (indicated by the minus signs), cleavage sites were enhanced by exposure to the various topoisomerase II–targeted agents (indicated by the plus signs). Specified reactions were incubated for an additional 10 minutes at 75°C before the addition of SDS in order to examine the stability of the cleavage complexes formed. The nucleotide 1484 is on the 5' side of the cleavage site (–1 position), which corresponds to the der(15) and der(17) translocation breakpoints in four patients with mitoxantrone-related APL. Panel B shows DNA topoisomerase II–mediated cleavage of the normal homologue of the der(15) and der(17) RARA translocation breakpoints in APL in Patient 1. The substrate spanning positions 2603 to 2871 of RARA intron 2 (GenBank accession number AJ297538 [GenBank] ) contained the translocation breakpoints. The nucleotide 2695 indicates the (–1) position of the cleavage site corresponding to the der(15) and der(17) translocation breakpoints.

 
The 8-bp translocation breakpoint hot spot at positions 1482 to 1489 corresponded to a topoisomerase II–mediated cleavage site at position 1484, where the position indicates the base immediately 5' to the cleavage (–1 position). Cleavage at position 1484 was detected in the absence of drug, but it was markedly enhanced by etoposide, both etoposide metabolites, and mitoxantrone. Position 1484 was a preferred site of cleavage by topoisomerase II in the presence of mitoxantrone, as evidenced by the intensity of the cleavage band (Figure 3A). Mitoxantrone-induced cleavage was enhanced by a factor of 8.9 and 2.5, respectively, relative to cleavage at this site without drug or in the presence of etoposide. Cleavage at many sites decreased substantially or was eliminated after heating (Figure 3A). By contrast, the mitoxantrone-induced cleavage at position 1484 remained detectable after heating (Figure 3A), indicating stability of the cleavage complexes. These results show that the PML intron 6 translocation breakpoint hot spot in mitoxantrone-related APL is a preferred and stable mitoxantrone-induced site of cleavage by topoisomerase II.

RARA Translocation Breakpoints in Mitoxantrone-Related APL

We performed in vitro topoisomerase II cleavage assays on double-stranded DNA substrates spanning the normal homologues of the RARA translocation breakpoints in Patients 1, 2, 3, and 4 to determine whether topoisomerase II also mediated the breakage at the RARA locus (Figure 3B and Table 1). In Patient 1 (Figure 3B), topoisomerase II–mediated cleavage was observed at position 2695 of the RARA intron 2 proximal to the der(15) and der(17) RARA translocation breakpoints and was heat-stable (Figure 3B). The RARA breakpoints on both derivative chromosomes in specimens from Patients 2, 3, and 4 were also at, or proximal to, sites of functional mitoxantrone-induced cleavage by topoisomerase II (Table 1). Assays on all substrates were repeated, and the repeated assays confirmed these results.

Sites of Mitoxantrone-Induced Cleavage by Topoisomerase II and t(15;17) Breakpoint Junctions

We used the functional sites of topoisomerase II–mediated cleavage of DNA at the translocation breakpoints to generate a model for the formation of the t(15;17), incorporating known repair mechanisms of breaks in double-stranded DNA. Figure 4 shows how recombination of mitoxantrone-enhanced cleavage sites at PML position 1484 and RARA position 2695 would form the der(15) and der(17) genomic breakpoint junctions identified in the APL in Patient 1. The sites of topoisomerase II–mediated cleavage of each DNA strand are four bases apart, thereby creating 5' overhangs,⁸ as shown in Figure 4. In the model, repair of the overhangs in PML and RARA entails exonucleolytic digestion, pairing of complementary bases, and joining of the DNA free ends by means of the NHEJ pathway, with template-directed polymerization to fill in any gaps. Models were also generated showing that mitoxantrone-induced cleavage by topoisomerase II formed the der(15) and der(17) breakpoint junctions in the leukemias in Patients 2, 3, and 4 (data not shown).

View larger version (15K): [in this window] [in a new window]   Figure 4. Model of the Formation of der(15) and der(17) Breakpoint Junctions in APL in Patient 1. Native PML and RARA sequences are red and blue, respectively. The model includes exonucleolytic processing to form two-base homologies in the case of der(15) and single-base homology in the case of der(17) and the creation of both breakpoint junctions by means of the error-prone nonhomologous end-joining repair pathway. During the formation of der(15), positions 1487 to 1488 on the antisense strand of PML are lost through exonucleolytic processing (pink) before the nonhomologous end-joining pathway joins the indicated bases. Positions 1485 to 1487 on the sense strand of PML are lost by exonucleolytic processing (pink), and der(17) forms through the nonhomologous end-joining pathway. Template-directed polymerization of the relevant single-stranded overhangs fills in any gaps (light blue). Each RARA overhang is completely preserved.

 
PML and RARA Translocation Breakpoints in Etoposide- and Doxorubicin-Related APL

A fifth patient (Patient 5) received a diagnosis of APL after being treated with etoposide and doxorubicin for laryngeal cancer (Table 1). Study of the breakpoint junction sequences indicated that the translocation occurred with the loss of a single G nucleotide from RARA (position 16089) (Figure 1A in the Supplementary Appendix, available with the full text of this article at www.nejm.org). Short sequence homologies were observed in PML and RARA characteristic of DNA repair by the NHEJ pathway. In the in vitro assay, etoposide, its catechol and quinone metabolites, and doxorubicin induced topoisomerase II–mediated cleavage at the PML and RARA translocation breakpoints. Cleavage was shown to be heat-stable with each of these drugs at the PML breakpoint (Figure 1B in the Supplementary Appendix) and with etoposide quinone at the RARA breakpoint (Figure 1C in the Supplementary Appendix). A model (Figure 1D in the Supplementary Appendix) indicated how recombination of cleavage sites at PML position 1239 and RARA position 16089 would form the der(15) and der(17) genomic breakpoint junctions in this case of APL.

Discussion

Leukemia characterized by balanced translocations, including t(15;17), can be a complication of treatment with anticancer drugs that poison topoisomerase II.^29,30 The mechanism by which these drugs predispose patients to leukemia remains in dispute. Some evidence supports a direct role for topoisomerase II in causing the DNA damage that leads to chromosomal rearrangements.^6,23,24,31 An indirect mechanism involving the induction of apoptosis-inducing nucleases has also been proposed.^32,33,34,35

Few genomic breakpoint junctions have been characterized in therapy-related APL.³⁶ Our study of the der(15) and der(17) genomic breakpoint junctions in APL arising after mitoxantrone treatment revealed clustering of breakpoints in the PML gene within an 8-bp region in intron 6, a result consistent with the existence of a translocation breakpoint hot spot. The PML-RARA rearrangements occurred without the gain or loss of any bases relative to the native genes, indicating that the translocation breakpoints in intron 6 were the sites of DNA damage.²⁴ Interestingly, one patient (Patient 3) received only 15 mg of mitoxantrone. This finding is consistent with the absence of a dose–response effect in the development of leukemia that follows epipodophyllotoxin treatment³⁷ and the detection of a leukemia-associated MLL translocation after a low total dose of doxorubicin.³⁸

The mitoxantrone-related PML translocation breakpoint hot spot corresponded with a preferred site of topoisomerase II–mediated cleavage that was not religated after heating. In vitro, mitoxantrone stimulated cleavage at the translocation breakpoint hot spot that was nine times that observed in the absence of the drug. The RARA translocation breakpoints in each of the four patients with mitoxantrone-related APL investigated by functional assays were also found to correspond to mitoxantrone-induced sites of cleavage of DNA by topoisomerase II. Models were devised in which recombination of broken DNA at sites of topoisomerase II–mediated cleavage formed the der(15) and der(17) breakpoint junctions. These studies indicate that mitoxantrone induces cleavage of PML and RARA by topoisomerase II and that this cleavage resulted in the observed translocation breakpoint junctions in mitoxantrone-related APL.

To determine whether topoisomerase II–mediated cleavage is relevant to other drugs in therapy-related APL, we evaluated a patient in whom APL developed after exposure to etoposide and doxorubicin. Etoposide and its metabolites and doxorubicin induced topoisomerase II to cleave DNA at the PML and RARA translocation breakpoints. The cleavage sites could recombine to form the der(15) and der(17) breakpoint junctions observed in this patient. These results suggest that topoisomerase II–mediated cleavage is a general mechanism causing DNA damage in APL that develops after treatment with various agents that target topoisomerase II.

Recent reports of treatment-related APL indicate that epirubicin and mitoxantrone are the most common antecedent drugs and that a substantial proportion of the patients had breast cancer.^17,18,19 Although etoposide is implicated in some cases of treatment-related APL,^17,18,19,36 this drug is more often associated with MLL translocations that disrupt band 11q23.^30,39 These observations suggest that different chemotherapeutic agents predispose patients to different translocations. A key question is how such specificity is conferred. Our in vitro assays show that mitoxantrone and etoposide or its metabolites stimulate topoisomerase II to cleave different sites in PML and RARA, implying the existence of different genomic hot spots for topoisomerase II–mediated cleavage in the presence of the different drugs. It is likely that such hot spots occur throughout the genome but that only translocations that confer a proliferative or survival advantage in an appropriate hematopoietic progenitor lead to leukemia. The identification of this translocation mechanism has important implications for the chemotherapy of cancer.

Dr. Mistry was supported by a Medical Research Council studentship and the Generation Trust, Department of Medical and Molecular Genetics, Guy's, King's, and St. Thomas' School of Medicine, and a travel award from the British Society for Haematology. Dr. Felix and Dr. Blair were supported by a grant from the National Institutes of Health (R01 CA77683). Dr. Felix was supported by grants (R01 CA80175, R0185469) from the National Institutes of Health, a Leukemia and Lymphoma Society Translational Research Award, a Leukemia and Lymphoma Society Specialized Center of Research grant, the Joshua Kahan Foundation, and the Friends of the Joseph Claffey Fund. Dr. Felix was also supported in part by a grant from the Pennsylvania Department of Health. The views expressed in this article are those of the authors and do not necessarily represent the views of the Pennsylvania Department of Health. Drs. Grimwade, Cross, and Mason were supported by the Leukaemia Research Fund of Great Britain. Dr. Reiter and Mr. Walz were supported by the Forschungsfonds der Fakultät für Klinische Medizin Mannheim der Universität Heidelberg and the German Bundesminister für Bildung und Forschung through the Kompetenznetz "Akute und chronische Leukämien" (Förderkennzeichen: 01GI0270). Dr. Wiemels is a Scholar of the Leukemia and Lymphoma Society, and Drs. Wiemels and Segal were supported by a grant (CA89032) from the National Institutes of Health. Dr. Osheroff was supported by a grant (GM33944) from the National Institutes of Health.

We are indebted to Jo Ann Byl for preparing the human topoisomerase II used in this study.

Source Information

From the Department of Medical and Molecular Genetics, Guy's, King's, and St. Thomas' School of Medicine, London (A.R.M., A.M., E.S., D.G.); the Division of Oncology, Children's Hospital of Philadelphia, Philadelphia (C.A.F., R.J.W.); the Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia (C.A.F.); Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany (A.R., C.W.); Unité de Biologie Cellulaire, Service de Médecine Nucléaire, Hôpital St. Louis, Paris (B.C., A.P., C.C.); the Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco (J.L.W., M.R.S.); Hôpital Avicenne–Paris 13 Université, Bobigny, France (L.A., P.F.); the Center for Cancer Pharmacology, University of Pennsylvania, Philadelphia (I.A.B.); the Departments of Biochemistry and Medicine, Vanderbilt University School of Medicine, Nashville (N.O.); the Department of Haematology, John Radcliffe Hospital, Oxford, United Kingdom (A.J.P.); Institut Paoli-Calmettes, INSERM UMR 599, and Université de la Méditerranée, Marseille, France (M.L.-P.); Wessex Regional Genetics Laboratory, Salisbury, United Kingdom (N.C.P.C.); and the Department of Haematology, University College London Hospitals, London (D.G.).

Address reprint requests to Dr. Grimwade at the Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, 8th Fl., Guy's Tower, Guy's Hospital, London SE1 9RT, United Kingdom, or at david.grimwade{at}genetics.kcl.ac.uk.

References

1. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:497-529. [Medline]
2. Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 2001;1:245-250. [CrossRef][Medline]
3. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 2003;17:71-97. [CrossRef][ISI][Medline]
4. Piazza F, Gurrieri C, Pandolfi PP. The theory of APL. Oncogene 2001;20:7216-7222. [CrossRef][ISI][Medline]
5. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909-1912. [Free Full Text]
6. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001;36:525-535. [CrossRef][ISI][Medline]
7. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 2002;33:331-345. [CrossRef][ISI][Medline]
8. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000;64:221-253. [ISI][Medline]
9. Negrini M, Felix CA, Martin C, et al. Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia. Cancer Res 1993;53:4489-4492. [Free Full Text]
10. Ahuja HG, Felix CA, Aplan PD. Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations. Genes Chromosomes Cancer 2000;29:96-105. [CrossRef][ISI][Medline]
11. Domer PH, Head DR, Renganathan N, Raimondi SC, Yang E, Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 1995;9:1305-1312. [ISI][Medline]
12. Aplan PD, Chervinsky DS, Stanulla M, Burhans WC. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 1996;87:2649-2658. [Free Full Text]
13. Strissel PL, Strick R, Rowley JD, Zeleznik-Le NJ. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 1998;92:3793-3803. [Free Full Text]
14. Zhang Y, Strissel P, Strick R, et al. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A 2002;99:3070-3075. [Free Full Text]
15. Dong S, Geng JP, Tong JH, et al. Breakpoint clusters of the PML gene in acute promyelocytic leukemia: primary structure of the reciprocal products of the PML-RARA gene in a patient with t(15;17). Genes Chromosomes Cancer 1993;6:133-139. [Medline]
16. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-2333. [Free Full Text]
17. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123-2137. [Free Full Text]
18. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972-1976. [Free Full Text]
19. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:395-400. [CrossRef][ISI][Medline]
20. Carli PM, Sgro C, Parchin-Geneste N, et al. Increase therapy-related leukemia secondary to breast cancer. Leukemia 2000;14:1014-1017. [CrossRef][Medline]
21. Reiter A, Saussele S, Grimwade D, et al. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer 2003;36:175-188. [CrossRef][Medline]
22. Grimwade D, Howe K, Langabeer S, et al. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. Br J Haematol 1996;94:557-573. [Medline]
23. Lovett BD, Strumberg D, Blair IA, et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 2001;40:1159-1170. [CrossRef][Medline]
24. Whitmarsh RJ, Saginario C, Zhuo Y, et al. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene 2003;22:8448-8459. [CrossRef][Medline]
25. Segal MR, Wiemels JL. Clustering of translocation breakpoints. J Am Stat Assoc 2002;97:66-76. [CrossRef]
26. Glaz J, Naus JI, Wallenstein S. Scan statistics. New York: Springer-Verlag, 2001.
27. Loader CR. Large deviation approximations to the distribution of scan statistics. Adv Appl Probab 1991;23:751-71.
28. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003;3:639-649. [CrossRef][ISI][Medline]
29. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52. [Free Full Text]
30. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994;83:2780-2786. [Free Full Text]
31. Lovett BD, Lo Nigro L, Rappaport EF, et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci U S A 2001;98:9802-9807. [Free Full Text]
32. Betti CJ, Villalobos MJ, Diaz MO, Vaughan AT. Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. Cancer Res 2001;61:4550-4555. [Free Full Text]
33. Betti CJ, Villalobos MJ, Diaz MO, Vaughan AT. Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division. Cancer Res 2003;63:1377-1381. [Free Full Text]
34. Eguchi-Ishimae M, Eguchi M, Ishii E, et al. Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals. Blood 2001;97:737-743. [Free Full Text]
35. Stanulla M, Wang J, Chervinsky DS, Thandla S, Aplan PD. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol 1997;17:4070-4079. [Abstract]
36. Kudo K, Yoshida H, Kiyoi H, Numata S, Horibe K, Naoe T. Etoposide-related acute promyelocytic leukemia. Leukemia 1998;12:1171-1175. [CrossRef][Medline]
37. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-577. [Free Full Text]
38. Megonigal MD, Cheung NK, Rappaport EF, et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci U S A 2000;97:2814-2819. [Free Full Text]
39. Bloomfield CD, Archer KJ, Mrozek K, et al. 11q23 Balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:362-378. [CrossRef][Medline]

Abstract PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Pedersen-Bjergaard, J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This article has been cited by other articles:

• Raffaghello, L., Lee, C., Safdie, F. M., Wei, M., Madia, F., Bianchi, G., Longo, V. D. (2008). From the Cover: Reactive Oxygen Species Special Feature: Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. USA 105: 8215-8220 [Abstract] [Full Text]  
• Flaig, T. W., Tangen, C. M., Hussain, M. H.A., Stadler, W. M., Raghavan, D., Crawford, E. D., Glode, L. M. (2008). Randomization Reveals Unexpected Acute Leukemias in Southwest Oncology Group Prostate Cancer Trial. JCO 26: 1532-1536 [Abstract] [Full Text]  
• Bottger, S., Jerszyk, E., Low, B., Walker, C. (2008). Genotoxic Stress-Induced Expression of p53 and Apoptosis in Leukemic Clam Hemocytes with Cytoplasmically Sequestered p53. Cancer Res. 68: 777-782 [Abstract] [Full Text]  
• Huang, R. S., Duan, S., Bleibel, W. K., Kistner, E. O., Zhang, W., Clark, T. A., Chen, T. X., Schweitzer, A. C., Blume, J. E., Cox, N. J., Dolan, M. E. (2007). A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Natl. Acad. Sci. USA 104: 9758-9763 [Abstract] [Full Text]  
• Nabhan, C. (2007). It Is Follicular... . So, Why CHOP?. JCO 25: 915-916 [Full Text]  
• Walz, C., Metzgeroth, G., Haferlach, C., Schmitt-Graeff, A., Fabarius, A., Hagen, V., Prummer, O., Rauh, S., Hehlmann, R., Hochhaus, A., Cross, N. C.P., Reiter, A. (2007). Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene. haematol 92: 163-169 [Abstract] [Full Text]  
• Malik, M., Nitiss, K. C., Enriquez-Rios, V., Nitiss, J. L. (2006). Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.. Molecular Cancer Therapeutics 5: 1405-1414 [Abstract] [Full Text]  
• Storlazzi, C. T., Fioretos, T., Surace, C., Lonoce, A., Mastrorilli, A., Strombeck, B., D'Addabbo, P., Iacovelli, F., Minervini, C., Aventin, A., Dastugue, N., Fonatsch, C., Hagemeijer, A., Jotterand, M., Muhlematter, D., Lafage-Pochitaloff, M., Nguyen-Khac, F., Schoch, C., Slovak, M. L., Smith, A., Sole, F., Van Roy, N., Johansson, B., Rocchi, M. (2006). MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. Hum Mol Genet 15: 933-942 [Abstract] [Full Text]  
• Weinstock, D. M., Elliott, B., Jasin, M. (2006). A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair. Blood 107: 777-780 [Abstract] [Full Text]  
• Ribeiro, R. C., Rego, E. (2006). Management of APL in Developing Countries: Epidemiology, Challenges and Opportunities for International Collaboration. ASH Education Book 2006: 162-168 [Abstract] [Full Text]  
• Gale, R. E., Hills, R., Pizzey, A. R., Kottaridis, P. D., Swirsky, D., Gilkes, A. F., Nugent, E., Mills, K. I., Wheatley, K., Solomon, E., Burnett, A. K., Linch, D. C., Grimwade, D., for the NCRI Adult Leukaemia Working Party, (2005). Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106: 3768-3776 [Abstract] [Full Text]  
• Pedersen-Bjergaard, J. (2005). Insights into Leukemogenesis from Therapy-Related Leukemia. NEJM 352: 1591-1594 [Full Text]